, Volume 67, Issue 17, pp 2481–2485 | Cite as

Comment on “Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal”



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Oettle H, Neuhaus P. Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 2007; 67(16): 2293–310PubMedCrossRefGoogle Scholar
  2. 2.
    Neoptolemos J, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in respectable pancreatic cancer: a randomized controlled trial. Lancet 2001; 358: 1576–85PubMedCrossRefGoogle Scholar
  3. 3.
    Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 2001; 358: 1565–6PubMedCrossRefGoogle Scholar
  4. 4.
    Neoptolemos J, Stocken D, Friess H, et al. A randomized trial of chemoradiotheapy and chemotherapy after resection of pancreatic cancer. New Engl J Med 2004; 350: 1200–8PubMedCrossRefGoogle Scholar
  5. 5.
    Abrams RA, Yeo CJ. Combined modality adjuvant therapy for resected periampullary pancreatic and nonpancreatic adenocarcinomas: a review of studies and experience at the Johns Hopkins Hospital, 1991–2003. Surg Oncol Clin N Am 2004; 13: 621–38PubMedCrossRefGoogle Scholar
  6. 6.
    Dickler A, Abrams RA. Radiochemotherapy in the management of pancreatic cancer. Part II: use in adjuvant and locally unresectable settings. Semin Radiat Oncol 2005; 15: 235–44Google Scholar
  7. 7.
    Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899–903PubMedCrossRefGoogle Scholar
  8. 8.
    Baakevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater: results of a controlled, prospective, randomized multicentre study. Eur J Cancer 1992; 29: 689–703Google Scholar
  9. 9.
    Klinkenbijl J, Jeekel J, Sahmound T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776–84PubMedCrossRefGoogle Scholar
  10. 10.
    Regine WF, Abrams R. Adjuvant therapy for pancreatic cancer: back to the future. Int J Radiat Oncol Biol Phys 1998; 42: 59–63PubMedCrossRefGoogle Scholar
  11. 11.
    Abrams RA, Winter KA, Regine WF, et al. RTOG 9704: radiotherapy quality assurance (QA) review and survival. Int J Radiat Oncol Biol Phys 2006; 66 Suppl. 3: S22Google Scholar
  12. 12.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative intent resection of pancreatic cancer: a multicenter randomized controlled trial. JAMA 2007; 297: 267–77PubMedCrossRefGoogle Scholar
  13. 13.
    Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single institution experience. Ann Surg 1997; 225: 621–36Google Scholar
  14. 14.
    Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic adenocarcinomas. Cancer 1990; 66: 56–61PubMedCrossRefGoogle Scholar
  15. 15.
    Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm: general principles. Nat Clin Pract Oncol 2007 Feb; 4(2): 86–100PubMedCrossRefGoogle Scholar
  16. 16.
    Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreas cancer. Semin Oncol 1994 Aug; 21 (4 Suppl. 7): 58–66PubMedGoogle Scholar
  17. 17.
    Lidestahl A, Permert J, Linder S, et al. Efficacy of systemic therapy in advanced pancreatic carcinoma. Acta Oncol 2006; 45(2): 136–43PubMedCrossRefGoogle Scholar
  18. 18.
    Xiong HQ, Carr K, Abbruzzese JL. Cytotoxic chemotherapy for pancreatic cancer: advances to date and future directions. Drugs 2006; 66(8): 1059–72PubMedCrossRefGoogle Scholar
  19. 19.
    Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408–12PubMedCrossRefGoogle Scholar
  20. 20.
    Ferrone CR, Finkelstein DM, Thayer SP. Perioperative CA19-9 levels can predict stage and survivalin patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006; 24: 2897–902PubMedCrossRefGoogle Scholar
  21. 21.
    Boeck S, Stieber P, Holdenrieder S, et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70: 255–64PubMedCrossRefGoogle Scholar
  22. 22.
    Brennan MF, Kattan MW, Klimstra D, et al. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004; 240: 293–8PubMedCrossRefGoogle Scholar
  23. 23.
    Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002 Apr 11; 346(15): 1128–37PubMedCrossRefGoogle Scholar
  24. 24.
    Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349: 2117–27PubMedCrossRefGoogle Scholar
  25. 25.
    Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004; 198: 722–31PubMedCrossRefGoogle Scholar
  26. 26.
    Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995 Jun; 221(6): 721–31PubMedCrossRefGoogle Scholar
  27. 27.
    Heidelberger C, Griesbach L, Montag BJ, et al. Studies on fluorinated pyrmidines II: effects on transplanted tumors. Cancer Res 1958; 18: 305–17PubMedGoogle Scholar
  28. 28.
    Moertel CG, Frytak S, Hang RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. Cancer 1981; 48: 1705–10PubMedCrossRefGoogle Scholar
  29. 29.
    Moertel CG, Childs Jr DS, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969 Oct 25; II(7626): 865–7CrossRefGoogle Scholar
  30. 30.
    Childs DS, Moertel CG, Holbrook MA, et al. Treatment of malignant neoplasms of the gastrointestinal tract with a combination of 5-fluorouracil and radiation: a randomized double-blind study. Radiology 1965; 84: 843–8PubMedGoogle Scholar
  31. 31.
    Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Nat Cancer Inst 1988; 80: 751–5CrossRefGoogle Scholar
  32. 32.
    Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node positive premenopausal women with breast cancer. N Engl J Med 1997; 337(14): 956–62PubMedCrossRefGoogle Scholar
  33. 33.
    Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high risk premenopausal women with breast cancer who received chemotherapy. N Engl J Med 1997; 337(14): 949–55PubMedCrossRefGoogle Scholar
  34. 34.
    Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high grade non-Hodgkin’s lymphoma. N Engl J Med 1998; 339: 21–6PubMedCrossRefGoogle Scholar
  35. 35.
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10: 890–5PubMedGoogle Scholar
  36. 36.
    Pignon JP, Arriagada R, Ihde DC, et al. A metaanalysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618–24PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of Radiation OncologyRush University Medical CenterChicagoUSA

Personalised recommendations